Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine plus R-ICE in R/R DLBCL
NCT03450343Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Apr 2019
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in diffuse large B-cell lymphoma (DLBCL), sponsored by Medical University of South Carolina. Primary endpoint: Dose Limiting Toxicity at 126 days. Started Apr 2019; status: completed.
02
Drugs
azacitidine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03450343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450343.